Gilead, Whistleblowers Settle Hepatitis Drug Kickback Claims

July 29, 2021, 1:33 PM

Gilead Sciences Inc. and two former sales managers have settled a False Claims Act suit accusing the company of engaging in a kickback scheme to induce physicians to increase hepatitis drug prescriptions.

Judge Mark A. Kearney of the U.S. District Court for the Eastern District of Pennsylvania ordered the case dismissed Wednesday in light of the parties’ agreement.

Terms of the settlement weren’t made available. Representatives for the parties didn’t immediately respond to a request for comments.

Whistleblowers Chris Purcell and Kimberly Groom, who filed their suit in August 2017, alleged that Gilead conditioned speaker program payments to physicians on ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.